{"classes":[{"categories":[{"measurements":[{"comment":"The upper confidence bound could not be estimated because there were insufficient events beyond the median survival time.","groupId":"OG000","lowerLimit":"13.1","upperLimit":"NA","value":"20.8"},{"comment":"The upper confidence bound could not be estimated because there were insufficient events beyond the median survival time.","groupId":"OG001","lowerLimit":"7.7","upperLimit":"NA","value":"18.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Female"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.0","upperLimit":"26.2","value":"17.1"},{"groupId":"OG001","lowerLimit":"10.3","upperLimit":"24.1","value":"13.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"79"}],"units":"Participants"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"description":"NIH-required analysis. A disease event is defined as local/regional persistence or recurrence of the cancer under study, distant metastases, a new second primary cancer, or death due to any cause. Participants undergoing surgery who had an R2 resection and participants not undergoing surgery who had a positive endoscopic biopsy or no biopsy at all were considered to have local persistence of disease. Disease-free survival time is defined as time from randomization to the date of first disease event or last known follow-up (censored). Rates are estimated by the Kaplan-Meier method. Analysis was to occur after 162 events were reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab","id":"OG000","title":"Chemoradiation and Trastuzumab (Arm 1)"},{"description":"Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery","id":"OG001","title":"Chemoradiation (Arm 2)"}],"paramType":"MEDIAN","populationDescription":"Eligible randomized participants. Data were stratified by sex.","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 8.0 years.","title":"Disease-free Survival (DFS) by Sex","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months"}